# US 2013/0157302 A1 · Method for determining capability of a compound for inhibiting a receptor using codon-optimized nucleic acid

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0157302 A1
- Document ID: US20130157302A1
- Status: Published application
- Kind: A1
- Application number: 13/761,174
- Filed: 2013-02-07
- Published: 2013-06-20
- Earliest claimed: 2009-01-29
- Assignees: Jnc Corporation
- Inventors: SATOSHI INOUYE; YUIKO SAHARA; JUNICHI SATO
- Web page: https://patentgrep.com/patent/US20130157302A1

## CPC

- C12P 21/02: having a known sequence of two or more amino acids, e.g. glutathione
- C07K 14/43595: {from coelenteratae, e.g. medusae}
- C12N 15/67: General methods for enhancing the expression
- C12Q 1/025: {for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics (antimicrobial activity C12Q1/18)}
- G01N 2333/43595: from coelenteratae, e.g. medusae
- C12P: FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE {(brewing of beer C12C; producing vinegar C12J; producing specific peptides or proteins C07K; producing enzymes C12N9/00; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; measuring or testing processes involving enzymes or microorganisms C12Q; measuring or testing processes involving nucleic acid amplification reactions C12Q1/6844; fermentation processes to form a food composition, A21 or A23; compounds in general, see the relevant compound class, e.g. C01, C07)}
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

A method for determining a capability of a compound for inhibiting a receptor through a change of intracellular calcium ion when the receptor is activated is provided. Contacting a host cell genetically engineered to express an apo-clytin-II protein generated from a codon-optimized nucleic acid with a test compound, and then determining an amount of light generated. The intracellular calcium ion can be detected much more easily.

## Claims

### Claim 1

A method for determining a capability of a compound for inhibiting a receptor through a change of intracellular calcium ion when the receptor is activated, the method comprising:
providing a host cell comprising the receptor, and the host cell genetically engineered to express an apo-clytin-II protein coded from a codon-optimized nucleic acid, wherein said codon optimized nucleic acid is SEQ ID NO:3;
contacting the host cell with coelenterazine or a derivative of coelenterazine;
adding the compound to and incubating with the host cell; and
determining an amount of light generated from the host cell.

### Claim 2 (depends on 1)

The method of claim 1, wherein the receptor is an ion-channel-related protein.

### Claim 3 (depends on 1)

The method of claim 1, wherein the receptor is a G-protein coupled receptor.

### Claim 4 (depends on 1)

The method of claim 1, wherein the host cell is a HEK293 cell or a CHO cell.

### Claim 5 (depends on 1)

The method of claim 1 further comprising recording the capability for inhibiting the receptor which is based on the amount of the light generated.
